Serum EV-miR-21-5p, miR-486-3p, MEG3 and XIST levels may correlate with disease progression and treatment response in patients with ALK-translocated lung adenocarcinoma prescribed ALK-TKI treatment (Figure 5). This evidence concerns the gene ALK and lung adenocarcinoma.